Related Experiment Videos

[Hodgkin's disease in childhood]

G Grazia1, P L Tarizzo, M Bianchi

  • 1Divisione di Pediatria Oncologica, Università degli Studi di Torino.

Minerva Pediatrica
|December 1, 1992
PubMed

Insights

Hodgkin disease (HD) is a neoplastic syndrome confirmed by advanced techniques. Modern treatments offer over 95% survival, with reduced side effects and a focus on preventing secondary cancers.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Context:

  • Hodgkin disease (HD) is increasingly recognized as a neoplastic syndrome.
  • Advances in immunohistochemistry and cytogenetics confirm the monoclonal origin of Reed-Sternberg cells, the hallmark of HD.
  • Associations between pediatric HD and Epstein-Barr virus (EBV) positivity are noted, particularly in developed nations.

Purpose:

  • To review the histopathologic classification of Hodgkin disease.
  • To discuss the current management strategies for pediatric Hodgkin disease.
  • To evaluate treatment outcomes, sequelae, and long-term risks associated with Hodgkin disease therapy.

Summary:

  • Hodgkin disease is classified into four subtypes, with nodular sclerosis and mixed cellularity being more common in children.
  • Treatment involves combined chemotherapy and radiotherapy, yielding survival rates exceeding 95%.
  • Modern therapeutic approaches minimize treatment-related sequelae, such as impaired growth and organ function, by using lower doses and targeted radiation fields.

Impact:

  • Improved understanding of HD pathogenesis and classification aids in accurate prognosis and tailored therapeutic strategies.
  • High survival rates and reduced treatment toxicity in pediatric Hodgkin disease patients are achieved.
  • Long-term surveillance is crucial to monitor for and manage potential secondary malignancies, including leukemia and solid tumors, following treatment for Hodgkin disease.

Related Concept Videos